OVERALL SURVIVAL BENEFITS FOR COMBINING TARGETED THERAPY AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL-CELL-LUNG CANCER: A META-ANALYSIS OF PUBLISHED DATA.

Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.

BACKGROUND: Combining targeted therapy has been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but it is still unclear whether combining targeted therapy might offer any benefits against standard monotherapy with erlotinib.We thus performed a meta-analysis of randomized controlled trials to compare the e

read more

Antifungal Susceptibility and Candida sp. Biofilm Production in Clinical Isolates of HIV-Positive Brazilian Patients under HAART Therapy

The aim of the present study was to characterize biofilms formed by Candida spp.clinical isolates (n = 19), isolated from the oral mucosa of HIV-positive patients.For characterizing the biofilms formed by several Candida sp.strains, isolated from HIV-positive patients, in terms of formed biomass, matrix composition and antifungal susceptibility pro

read more